From Amgen to Gilead, drugmakers are sitting on billions of cash — and top pharma executives are hinting about big M&A to come in 2019

Indonesia Berita Berita

From Amgen to Gilead, drugmakers are sitting on billions of cash — and top pharma executives are hinting about big M&A to come in 2019
Indonesia Berita Terbaru,Indonesia Berita utama
  • 📰 BusinessInsider
  • ⏱ Reading Time:
  • 1 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 4%
  • Publisher: 51%

Billion-dollar deals from drug giants Eli Lilly & Co. and Bristol-Myers Squibb could set the tone for a year full of healthcare acquisitions.

Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

BusinessInsider /  🏆 729. in US

Indonesia Berita Terbaru, Indonesia Berita utama

Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.

U.S. top court rejects Amgen over cholesterol medication patent fightU.S. top court rejects Amgen over cholesterol medication patent fightThe U.S. Supreme Court on Monday declined to take up Amgen Inc's bid to rei...
Baca lebih lajut »

Amgen CEO on cholesterol drug price cut: 'Too many patients' were struggling to payAmgen CEO on cholesterol drug price cut: 'Too many patients' were struggling to payJim Cramer sits down with Amgen Chairman and CEO Bob Bradway to hear about the company's recent price cut for one of its key drugs.
Baca lebih lajut »

House Democrats launch drug-pricing probe into a dozen major health-care companiesHouse Democrats launch drug-pricing probe into a dozen major health-care companiesAbbVie, Amgen, AstraZeneca, Celgene, Eli Lilly, Johnson & Johnson, Mallinckrodt, Novartis, Novo Nordisk, Pfizer, Sanofi and Teva Pharmaceuticals received letters seeking detailed information and documents about the companies' pricing practices.
Baca lebih lajut »

U.S. lawmaker launches investigation into pharma drug pricingU.S. lawmaker launches investigation into pharma drug pricingRepresentative Elijah Cummings, who chairs the House Oversight Committee, sent letters to 12 drugmakers seeking information on price increases, investment in research and development, and corporate strategies to preserve market share and pricing power, his office said in a statement. Novo Nordisk, Amgen
Baca lebih lajut »

A Big, Fatty Opportunity for Big PharmaA Big, Fatty Opportunity for Big PharmaThe next multibillion-dollar therapeutic area for drug companies may be fatty liver disease, but there are a few practical hurdles to overcome first.
Baca lebih lajut »

U.S. top court rejects Amgen over cholesterol medication patent fightU.S. top court rejects Amgen over cholesterol medication patent fightThe U.S. Supreme Court on Monday declined to take up Amgen Inc's bid to rei...
Baca lebih lajut »

Box Office: 'Aquaman' Just Topped $1 Billion, And Here's A Big Reason WhyBox Office: 'Aquaman' Just Topped $1 Billion, And Here's A Big Reason WhyLike 'Wonder Woman' and 'Black Panther,' 'Aquaman' is a huge hit partially because it's the first movie starring that specific superhero.
Baca lebih lajut »

Box Office: 'Aquaman' Just Topped $1 Billion, And Here's A Big Reason WhyBox Office: 'Aquaman' Just Topped $1 Billion, And Here's A Big Reason WhyLike 'Wonder Woman' and 'Black Panther,' 'Aquaman' is a huge hit partially because it's the first movie starring that specific superhero.
Baca lebih lajut »



Render Time: 2025-04-14 20:49:41